Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110369 | 0.85 | AKR1B1 (0.52) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 | |
| SCHEMBL19866382 | 0.82 | TSHR (0.48) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 | |
| SCHEMBL4551579 | 0.82 | ALDH1A1 (0.47) | TSHRALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL2136831 | 0.79 | TSHR (0.50) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 | |
| SCHEMBL6822756 | 0.79 | TAAR1 (0.52) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 | |
| SCHEMBL31737298 | 0.79 | TAAR1 (0.52) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 | |
| SCHEMBL137678 | 0.79 | TSHR (0.45) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 | |
| SCHEMBL2660504 | 0.76 | AKR1B1 (0.45) | AKR1B1SMN1; SMN2TAAR1GAALMNA | |
| SCHEMBL10636626 | 0.76 | TSHR (0.46) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 | |
| SCHEMBL9117779 | 0.76 | TSHR (0.42) | TSHRALDH1A1AKR1B1SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106659162-A | 3, 6-dichlorosalicylic acid compounds and related synthetic methods | 孟山都技术公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-104710379-A | Synthetic method for BMS-191011 | UNIV SOUTH CHINA TECH | 2015-06-17 | — | — | CN | disclosed |
| CN-102557971-B | Substituted acids for the treatment of respiratory diseases | ASTRAZENECA AB | 2015-06-17 | — | — | CN | disclosed |
| CN-103403625-A | Charge control agent and toner for electrostatic image development containing same | ORIENT CHEMICAL IND | 2013-11-20 | — | — | CN | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2220095-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| EP-1644025-A4 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | VION PHARMACEUTICALS INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1644025-A1 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | Vion Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005004897-A1 | WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS | VION PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| CN-1054365-C | Preparation of hydroxy benzaldehyde compound | RHONE POULENC CHIMIE (FR) | 2000-07-12 | — | — | CN | disclosed |
| US-5811559-A | Preparation of hydroxybenzaldehyes | RHONE-POULENC CHIMIE | 1998-09-22 | — | — | US | disclosed |
| US-5689009-A | OXIDATION OF THE CORRESPONDING BENZYL ALCOHOL, PLATINUM CATALYST, BORON AND BISMUTH COCATALYST, SALICYLALDEHYDE | RHONE-POULENC CHIMIE (FR) | 1997-11-18 | — | — | US | disclosed |
| CN-1111611-A | Preparation of hydroxy benzaldehyde compound | RHONE POULENC CHIMIE (FR) | 1995-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | TSHR 3152/4885ALDH1A1 1857/4885AKR1B1 1898/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | TSHR 4136/4885ALDH1A1 447/4885AKR1B1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.